Skip to main content

Table 4 Predictors of direct medical cost for prostate cancer during the first 12 months post-diagnosis

From: National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database

Variables

Unadjusted

Adjusted

Coefficient

P value

Coefficient

P value

Age, years

−0.0067

<.0001

−0.0015

<.0001

Income level, quintile

 Below poverty line (lowest)

 I

0.0012

0.9142

−0.0241

0.0144

 II

0.0070

0.5280

−0.0306

0.0025

 III

0.0297

0.0045

−0.0074

0.4403

 IV

0.0267

0.0071

−0.0136

0.1357

 V (highest)

0.0335

0.0003

0.0090

0.2886

Residential area

 Metropolitan

 Urban

0.0023

0.6586

0.0055

0.2516

 Rural

−0.0092

0.16

0.0156

0.0092

Charlson comorbidity index

 0

 1–2

0.0639

<.0001

0.0715

<.0001

 3–4

0.1377

<.0001

0.1572

<.0001

 ≥ 5

0.1791

<.0001

0.1957

<.0001

Primary treatment

 Surgery only

 Surgery+ADT

0.2549

<.0001

0.2570

<.0001

 Surgery+RT

0.3352

<.0001

0.3403

<.0001

 Surgery+ADT + RT

0.7928

<.0001

0.7961

<.0001

 RT only

0.5093

<.0001

0.4997

<.0001

 ADT only

−0.1133

<.0001

−0.1051

<.0001

 ADT + RT

0.5354

<.0001

0.5421

<.0001

Adjusted-R

  

0.1812

 
  1. ADT Androgen deprivation therapy, RT Radiotherapy, Multivariable adjusted models were adjusted for age, income level, residential area, Charlson comorbidity index, and primary treatment type
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us